« Back to Medicines list

Bactroban Nasal Ointment

  • Name:

    Bactroban Nasal Ointment

  • Company:
    info
  • Active Ingredients:

    Mupirocin calcium

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/02/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 13/3/2017
print

Print ViewKeyword Search SPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
Medicine Name Bexsero, suspension for injection in pre-filled syringe Active Ingredients Meningococcal group-B vaccine (rDNA, component, adsorbed)
Medicine Name Boostrix - Suspension for injection Active Ingredients Diphtheria, Tetanus and Pertussis vaccine
1 - 0 of 135 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 February 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 13 March 2017

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 13 March 2017 SPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.1 – summary of change: Update to the information regarding Mupirocin breakpoints.

Updated on 4 December 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 4 December 2015 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision
  • Change to MA holder contact details

Updated on 17 July 2015 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to address of the MA Holder

Updated on 17 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 2 July 2015 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·         Section 2 – Update to qualitative and quantitative composition statement

·         Section 4.2 – Minor QRD update

·         Section 4.4 - Amendments to the current approved text for the nasal ointment formulation for consistency with the text for the ointment formulation:

“This mupirocin nasal ointment formulation is not suitable for ophthalmic use.”

·         Section 4.6 – Minor QRD update

·         Section 4.8 – Addition of the term ‘anaphylaxis’; Updated HPRA details; QRD and minor editorial updates

·         Section 4.9 - Updated statements and management of overdose

·         Section 10 – Date of revision update

Updated on 2 July 2015 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to, or new use for medicine
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 7 April 2014 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

 

Changes to:

Section 4.4 - Special warnings and precautions for use,
Section 4.6 - Pregnancy and lactation,
Section 4.7 - Effects on ability to drive and use machines,
Section 4.8 - Undesirable effects,
Section 5.3 - Preclinical safety data,
Section 6.6 - Special precautions for disposal

 

Updated on 4 April 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 9 September 2013 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery

Updated on 19 June 2013 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to:

Section 4.1 -Therapeutic indications,
Section 5.1 - Pharmacodynamic properties

Updated on 30 August 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 6 May 2010 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

1.         Name of the Medicinal Product

 

            Bactroban Nasal Ointment 2%w/w

 

4.3       Contraindications

 

            Bactroban nasal ointment should not be given to patients with a history of hypersensitivity to any of the constituents.

 

Hypersensitivity to mupirocin or any of the excipients (see section 6.1).

 

4.4       Special Warnings and Special Precautions for Use

 

             Care should be taken to avoid the eyes.

           

            In the rare event of a possible sensitisation reaction or severe local irritation occurring with the use of Bactroban Nasal Ointment, treatment should be discontinued, the product should be wiped off and appropriate alternative therapy for the infection instituted.

 

Should a possible sensitisation reaction or severe local irritation occur with the use of Mupirocin Nasal Ointment, treatment should be discontinued, the product should be wiped away and appropriate therapy instituted.

 

As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.

 

Avoid contact with the eyes.  If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed.

 

4.5       Interaction with Other Medicinal Products and Other Forms of Interaction

 

            It is not known whether or not the product interacts with other medicaments.

 

No drug interactions have been identified.

 

4.6       Pregnancy and Lactation

 

            This product should not be used during pregnancy and lactation unless considered essential by the physician. 

           

            Pregnancy: Adequate human data on the use during pregnancy are not available. However animal studies have not identified any risk to pregnancy or embryo-foetal development.

 

            Lactation: Adequate human and animal data on use during lactation are not available.

 

Pregnancy

Reproduction studies on mupirocin in animals have revealed no evidence of harm to the foetus. As there is no clinical experience on its use during pregnancy, mupirocin should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.

 

Lactation

There is no information on the excretion of mupirocin in milk

 

4.7       Effects on Ability to Drive and Use Machines

 

            No adverse effects on the ability to drive or operate machinery have been observed identified.

 

4.9       Overdose

 

            The toxicity of mupirocin is very low.  In the event of overdose accidental ingestion, symptomatic treatment should be given.

Updated on 16 September 2009 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6 - Pharmaceutical particulars
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company


SUMMARY OF PRODUCT CHARACTERISTICS CHANGES (MARKED IN RED)

 

 

1.       Name of the Medicinal Product

 

            Bactroban Nasal Ointment 2%w/w

 

2.       Qualitative and Quantitative Composition

 

            Mupirocin 2.0% w/w as mupirocin calcium

            For a full list of excipients, see section 6.1

         

 

6.       Pharmaceutical Particulars

 

6.1     List of Excipients

 

            White soft paraffin

            Mixed diglycerinester of fatty acids (Softisan 649)

 

 

 

 

 

Updated on 26 August 2008 SPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 10:
 
Revision Date: September 2004

Updated on 8 July 2008 PIL

Reasons for updating

  • Addition of manufacturer

Updated on 4 August 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 14 December 2004 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 10 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 3 July 2003 SPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 June 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)